ALNY · Insider Trading
Alnylam Pharmaceuticals, Inc.
Every open-market purchase and sale reported by ALNY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-06 | Bryan Supran | EVP, CLO and Secretary | Sell | −1,758 | −$398.86K |
| 2026-09-22 | Yvonne Greenstreet | Chief Executive Officer | A | +107 | — |
| 2026-06-03 | Benjamin Cravatt | Director | A | +4,393 deriv. | — |
| 2026-06-03 | David E I Pyott | Director | MIXED | — | −$1.15M |
| 2026-05-22 | Stuart A Arbuckle | Director | A | +671 | — |
| 2026-05-22 | Dennis A Ausiello | Director | A | +671 | — |
| 2026-05-22 | Olivier Brandicourt | Director | A | +671 | — |
| 2026-05-22 | Margaret A Hamburg | Director | A | +671 | — |
| 2026-05-22 | Peter N Kellogg | Director | A | +671 | — |
| 2026-05-22 | David E I Pyott | Director | A | +671 | — |
| 2026-05-22 | Colleen F Reitan | Director | A | +671 | — |
| 2026-05-22 | Amy W Schulman | Director | A | +838 | — |
| 2026-05-22 | Charles Elliott Sigal | Director | A | +671 | — |
| 2026-05-14 | Amy W Schulman | Director | M | +11,250 | +$789.75K |
| 2026-04-07 | Melissa McLaughlin | Chief Human Resources Officer | Sell | −3,910 | −$1.27M |
| 2026-03-06 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | Sell | −1,291 | −$417.69K |
| 2026-03-06 | Tolga Tanguler | EVP, Chief Commercial Officer | Sell | −2,309 | −$745.98K |
| 2026-03-06 | Jeffrey V. Poulton | EVP, Chief Financial Officer | Sell | −2,468 | −$797.35K |
| 2026-03-06 | Yvonne Greenstreet | Chief Executive Officer | Sell | −2,933 | −$947.58K |
| 2026-03-06 | Pushkal Garg | EVP Chief R&D | Sell | −4,713 | −$1.52M |
| 2026-03-04 | Yvonne Greenstreet | Chief Executive Officer | MIXED | +7,045 | −$2.23M |
| 2026-03-04 | Bryan Supran | EVP, CLO and Secretary | A | +1,539 | — |
| 2026-03-04 | Tolga Tanguler | EVP, Chief Commercial Officer | MIXED | +3,171 | −$523.58K |
| 2026-03-04 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | MIXED | +438 | −$1.05M |
| 2026-03-04 | Pushkal Garg | EVP Chief R&D | MIXED | +1,277 | −$1.13M |
| 2026-03-04 | Jeffrey V. Poulton | EVP, Chief Financial Officer | MIXED | +2,563 | −$722.80K |
| 2026-03-02 | Pushkal Garg | EVP Chief R&D | MIXED | −2,719 | −$1.53M |
| 2026-03-02 | Tolga Tanguler | EVP, Chief Commercial Officer | M | +1,666 | — |
| 2026-03-02 | Jeffrey V. Poulton | EVP, Chief Financial Officer | M | +1,908 | — |
| 2026-03-02 | Yvonne Greenstreet | Chief Executive Officer | M | +5,921 | — |
| 2026-02-25 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | A | +158 | — |
| 2026-02-17 | Jeffrey V. Poulton | EVP, Chief Financial Officer | MIXED | +2,337 | −$695.20K |
| 2026-02-17 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | MIXED | — | −$1.28M |
| 2026-02-17 | Tolga Tanguler | EVP, Chief Commercial Officer | MIXED | +2,041 | −$607.45K |
| 2026-02-17 | Yvonne Greenstreet | Chief Executive Officer | MIXED | +7,251 | −$2.16M |
| 2026-02-17 | Pushkal Garg | EVP Chief R&D | MIXED | +2,337 | −$695.20K |
| 2026-01-14 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | MIXED | — | −$1.40M |
| 2026-01-14 | Tolga Tanguler | EVP, Chief Commercial Officer | MIXED | +2,290 | −$547.93K |
| 2026-01-14 | Jeffrey V. Poulton | EVP, Chief Financial Officer | MIXED | +3,413 | −$1.01M |
| 2026-01-14 | Yvonne Greenstreet | Chief Executive Officer | MIXED | +9,426 | −$3.48M |
| 2026-01-14 | Pushkal Garg | EVP Chief R&D | MIXED | +2,290 | −$547.93K |
| 2026-01-07 | Stuart A Arbuckle | Director | A | +3,279 deriv. | — |
| 2025-12-01 | Yvonne Greenstreet | Chief Executive Officer | MIXED | +3,576 | +$777 |
| 2025-11-19 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | MIXED | −3,967 | −$4.51M |
| 2025-11-14 | Yvonne Greenstreet | Chief Executive Officer | MIXED | — | −$8.61M |
| 2025-10-03 | Pushkal Garg | EVP Chief R&D | MIXED | — | −$2.69M |
| 2025-10-03 | Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | MIXED | +2,512 | −$1.10M |
| 2025-10-03 | Tolga Tanguler | EVP, Chief Commercial Officer | MIXED | +1,446 | −$635.13K |
| 2025-10-03 | Yvonne Greenstreet | Chief Executive Officer | MIXED | +9,188 | −$4.03M |
| 2025-10-03 | Jeffrey V. Poulton | EVP, Chief Financial Officer | MIXED | +3,931 | −$1.73M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Phillip A Sharp | Director | 266,899 | $61.88M |
| Yvonne Greenstreet | Chief Executive Officer | 96,209 | $22.30M |
| Jeffrey V. Poulton | EVP, Chief Financial Officer | 64,107 | $14.86M |
| Tolga Tanguler | EVP, Chief Commercial Officer | 36,398 | $8.44M |
| David E I Pyott | Director | 32,391 | $7.51M |
| Amy W Schulman | Director | 24,049 | $5.58M |
| Kevin Joseph Fitzgerald | CSO & EVP, Head of Research | 21,821 | $5.06M |
| Pushkal Garg | EVP Chief R&D | 20,874 | $4.84M |
| Michael W Bonney | Director | 20,804 | $4.82M |
| Bryan Supran | EVP, CLO and Secretary | 12,807 | $2.97M |
| Melissa McLaughlin | Chief Human Resources Officer | 11,729 | $2.72M |
| Robert W. Hesslein | EVP, CLO and Secretary | 8,002 | $1.86M |
| Dennis A Ausiello | Director | 5,082 | $1.18M |
| Charles Elliott Sigal | Director | 3,446 | $798.89K |
| Margaret A Hamburg | Director | 1,582 | $366.76K |
| Colleen F Reitan | Director | 1,446 | $335.23K |
| Olivier Brandicourt | Director | 1,446 | $335.23K |
| Peter N Kellogg | Director | 1,446 | $335.23K |
| Carolyn R Bertozzi | Director | 775 | $179.67K |
| Stuart A Arbuckle | Director | 671 | $155.56K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALNY quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.